drugset

drugset / Trial / NCT02142777

S-Equol in Alzheimer's Disease (SEAD) Trial

NCT02142777 ↗

Phase 1 Completed 15 enrolled Russell Swerdlow, MD Ausio Pharmaceuticals, LLC · collab

NaSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to determine if S-equol could benefit persons with Alzheimer's Disease (AD).

Timeline

Start: 2014-07
Primary completion: 2016-04
Completion: 2016-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AUS-131	Small molecule	10 mg	Oral

Indications